Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. COHR

Go back to Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24

February 21, 2025 12:23 PM EST

Piper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating and $24.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "We believe it's best to remain on the sidelines with HIMS following the FDA's announcement this morning that... More

Why Morgan Stanley is cautious on Hims & Hers shares

February 20, 2025 4:00 PM EST

Morgan Stanley remains cautious on Hims & Hers Health, Inc. (NYSE: HIMS) despite the companys latest move into at-home lab testing through its acquisition of Trybe Labs.

The investment bank maintains an Equal-weight rating on the stock, arguing that excitement around the companys growth potential may be outpacing realistic financial... More

Hims and Hers (HIMS) PT Raised to $21 at BofA Securities

February 20, 2025 5:18 AM EST

BofA Securities analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $21.00 (from $18.00) while maintaining a Underperform rating.

The analyst comments "HIMS observed sales per Bloomberg Second Measure (BSM) data grew 104% y/y in January and suggests GLP-1s... More